Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report released on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 2.7 %

Shares of Titan Pharmaceuticals stock opened at $6.88 on Wednesday. Titan Pharmaceuticals has a twelve month low of $5.00 and a twelve month high of $16.60. The stock has a market capitalization of $6.26 million, a price-to-earnings ratio of -0.84 and a beta of 1.32. The business’s 50 day simple moving average is $7.27 and its 200-day simple moving average is $7.05.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.